Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix announced preliminary unaudited revenue for Q4 2020 between $25 million and $27 million, a significant increase of 172% to 193% from Q3 2020's $9.2 million. The growth stems from enhanced COVID-19 testing, lung diagnostics, and biopharma services. Notably, a net $63 million was raised through an IPO, bolstering liquidity. Lung diagnostic testing revenue rose slightly to $3.5 million to $4 million, while COVID-19 testing services surged to $20 million to $21 million. Biodesix's strong cash position ensures operational stability into 2021.
Purdue University has partnered with Biodesix (Nasdaq: BDSX) to provide rapid COVID-19 antigen testing for over 20,000 off-campus students for the spring 2021 semester. Testing will occur from January 9 to January 22, with results available within 30 minutes via text. This initiative, part of the Protect Purdue program, aims to enhance health measures implemented during the fall semester.
Purdue covers testing costs, and different testing arrangements apply for students living on campus and faculty.
Biodesix, a key player in lung disease diagnostics, has appointed Ryan Siurek as the new Chief Accounting Officer, reporting to CFO Robin Harper Cowie. Siurek brings extensive experience from Vail Resorts and Sprint Corporation, where he held significant accounting roles. His arrival is geared towards supporting the company's growth strategies for 2021 and beyond. Biodesix is recognized for innovative diagnostic tests that leverage AI, including its Lung Reflex® strategy and SARS-CoV-2 tests, aimed at expediting treatment decisions for lung disease patients.
Biodesix (Nasdaq: BDSX) has launched the ALTITUDE biomarker study, focusing on the clinical utility of the Nodify XL2 test for low to moderate risk lung nodules, in line with the 2018 ATS guidelines for lung cancer detection. Led by Dr. Gerard Silvestri, the randomized controlled trial aims to enroll 2,000 patients, with interim results expected in 2022 and study completion anticipated by late 2023. This initiative is part of Biodesix's commitment to enhancing lung disease diagnostics, leveraging AI and multi-omics technologies.
Biodesix reported record revenue of $9.2 million for Q3 2020, a 133% increase from the previous year, primarily driven by $5.5 million from COVID-19 diagnostic tests. The company completed a successful IPO, raising approximately $63 million. However, operating loss decreased to $6.2 million, down 31% year-over-year. Research expenses rose by 15%, while total cash reserves increased to $6.3 million as of September 30, 2020. The strategic partnership for COVID-19 testing further highlights the company’s role in the pandemic response.
Biodesix, Inc. (Nasdaq: BDSX) announced the publication of a study validating its Nodify XL2 lung nodule test. This test improves clinical decision-making by identifying patients with a low risk of malignancy, thereby reducing unnecessary invasive procedures. The research confirms the test’s accuracy with a sensitivity of 97% and negative predictive value of 98%. After two years, benign nodules remained benign, affirming its effectiveness over time. The study published in the CHEST Journal underscores Biodesix's commitment to enhancing patient outcomes.
Biodesix, Inc. (Nasdaq: BDSX) has successfully closed its initial public offering (IPO) of 4,000,000 shares at a price of $18.00 per share, raising approximately $72.0 million in gross proceeds. The shares began trading on The Nasdaq Global Market on October 28, 2020. Morgan Stanley and William Blair led the offering, with Canaccord Genuity and BTIG participating as managers. The offering's registration has been declared effective by the U.S. Securities and Exchange Commission. This announcement does not constitute an offer to sell or buy the securities.
Biodesix (Nasdaq: BDSX) announced the pricing of its initial public offering (IPO) of 4,000,000 shares at $18.00 per share. Trading on The Nasdaq Global Market is set to begin on October 28, 2020, with the IPO expected to close on October 30, 2020, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 600,000 shares at the IPO price. Morgan Stanley and William Blair are the lead managers for this offering, which has been registered and declared effective by the U.S. Securities and Exchange Commission.